Navigation Links
Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
Date:9/8/2011

SAN FRANCISCO, Sept. 8, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that dosing began in a Phase 1 clinical study to evaluate multiple ascending doses of NKTR-181, the company's novel opioid analgesic drug candidate. NKTR-181 is in development as a once- or twice-daily oral tablet for the treatment of chronic pain, and is designed to address the abuse liability and serious central nervous system (CNS) side effects associated with current opioid therapies. Chronic pain conditions, such as osteoarthritis, back pain and cancer pain, affect at least 126 million adults in the U.S. annually and contribute to over $100 billion a year in lost productivity(1).

The multiple ascending dose study is the second study in the Phase 1 clinical program for NKTR-181.  The first study, a single ascending dose trial in 110 healthy subjects, was completed in July 2011.  Results from the first Phase 1 study will be presented at the 2011 American Academy of Pain Management (AAPM) Annual Clinical Meeting on September 21, 2011.

NKTR-181, a novel mu-opioid agonist with an extended pharmacokinetic profile, was created using Nektar's proprietary small molecule polymer conjugate technology.  With slower entry into the CNS when compared to published oxycodone data, NKTR-181 has the potential to greatly reduce the euphoria that underlies opioid abuse liability and dependence.  In addition, NKTR-181 is intended to reduce the other serious CNS-related side effects such as respiratory depression and sedation which are associated with current opioid therapies.  NKTR-181 is a new chemical entity created by small molecule polymer conjugation with unique properties that are inherent to its molecular structure.  As a result, NKTR-181 is also specifically designed to prevent its conversion into a more abusable opioid.

The primary objective of
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015  Kannalife Sciences, Inc. ("Kannalife") announces that ... Scientific Advisory Board to assist the Company in the ... use of cannabinoid therapeutics for the treatment of Chronic ... responsible for conducting the full autopsy of Mike ... for the Pittsburgh Steelers. It was through his examination ...
(Date:3/4/2015)... , Mar. 04, 2015 Research and Markets ... addition of the "Negative Pressure Wound Therapy ... Global Industry Analysis, Size, Share, Growth, Trends and ... offering. , The global negative ... types and by geography. By product types the ...
(Date:3/4/2015)... , March 4, 2015 Oramed ... ), a clinical-stage pharmaceutical company focused on the development ... company will participate in the upcoming 27 th ... Dana Point, CA.  Dr. ... of Oramed, will present a corporate overview on March ...
Breaking Medicine Technology:Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 2Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 3Global Negative Pressure Wound Therapy (Conventional and Single Use NPWT Systems) Market Report 2014-2020 2Oramed to Present at the ROTH Conference 2Oramed to Present at the ROTH Conference 3
... California and AMSTERDAM, July 21, 2011 , ... in,molecular cancer diagnostics, announced today that, together with,thought-leading ... has launched the RATHER (Rational Therapy for,Breast Cancer) ... will collectively receive nearly €12,million in funding from ...
... MEADVILLE, Pa., July 21, 2011 C&J Industries announced today the ... expansion. With these 2 Phases complete, C&J now has three Class ... Molding presses. These presses range in size from 20 Ton, ... the machines are Toshiba all-electric presses. C&J has also ...
Cached Medicine Technology:Agendia Receives €1.27 Million in Funding from the EU's Seventh Framework Programme 2Agendia Receives €1.27 Million in Funding from the EU's Seventh Framework Programme 3C&J Industries Completes Phases I and II of Building Expansion 2
(Date:3/4/2015)... York, New York (PRWEB) March 04, 2015 ... was reviewing the cardiovascular risks potentially associated with low ... Drug Administration (FDA) announced that it will now require ... may increase their risk for heart attacks and strokes. ... 3, 2015, the agency also stated that it was ...
(Date:3/4/2015)... " Optrix by Body Glove ” ... Tech Report, which takes a look at the latest ... Scott Steinberg, a special reporter for NewsWatch and a ... viewers how they have an ultra-rugged, waterproof case with ... a major player at the Consumer Electronics Show in ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 The popular ... of their new L-Style Revolution™ Program. The customized program ... and women of all health and fitness levels to ... goals faster than traditional methods. , “We’re really proud ... customized plans based on award winning techniques to help ...
(Date:3/4/2015)... 2015 Information Innovators Inc . ... has joined the company as Chief Technology Officer. ... focus for the company, including customer-centric strategies and initiatives, ... years of experience as a technology executive and visionary. ... at the FBI including oversight of enterprise data management, ...
(Date:3/4/2015)... In a small ceremony with 20 attendees and ... facility in New Port Richey on February 24, 2015 with ... allow the Florida drug detox facility to continue ... through treatment and education. “Due to our unique medical-detox process ... States, we made the decision that expanding our facility was ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4Health News:A Waterproof Phone Case with an Interchangeable Lens System was Featured on NewsWatch Television on January 30, 2015 2Health News:The Makers of Liporidex, The Popular Sports Nutrition Supplement Brand, Launches Its New L-Style Revolution™ Diet & Exercise Program That Promises Turbo Charged Results 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 3Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 2Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 3
... has been published in the World Journal of Gastroenterology ... was the first case of gastric carcinosarcoma obtained in ... admitted by Dr. Tomislav Randjelovic as surgeon and Dr. ... Dr. Randjelovic and his team; the anatomical and patoanatomical ...
... Nov. 14 MediNotes Corporation, a,leading provider of ... medical practices, today announced that MediNotes e reached,another ... Systems (PMS), using HL7 as the industry standard ... represents a 15%,increase in the amount of PMS ...
... launched at MEDICA in Germany, NEW YORK, Nov. ... leading developer of biosensor and microprocessor,technologies for use in ... PulseOx 6100(TM), two new oximetry devices, will,be formally introduced ... for,Medicine in Dusseldorf, Germany between 14th - 17th November, ...
... Tenn., Nov. 14 AT&T Inc. (NYSE: ... managed services to Howell Allen,Clinic, a six-location, neurosurgical ... serves patients in Nashville, middle,Tennessee, southern Kentucky and ... three-year contract, AT&T will deliver a robust,Managed Internet ...
... Region 5 has awarded a $40,000 grant to the ... improve conditions for,asthma sufferers., Specifically, the mission of ... emergency room visits, missed school and work days, and,deaths ... health and welfare of children and adults,who suffer from ...
... Innovative ... INDIANAPOLIS, Nov. 14 Anthem Blue Cross and Blue Shield,in ... that,incorporates public health data to identify and help address major ... to collaborate,with local and state officials, as well as community ...
Cached Medicine News:Health News:MediNotes EMR Now Interfaces With 76 Practice Management Systems, Allowing More Medical Practices to Replace Their Patients' Aging Paper Medical Records 2Health News:SPO Medical Unveils New Oximetry Devices for European Markets 2Health News:SPO Medical Unveils New Oximetry Devices for European Markets 3Health News:Howell Allen Clinic Selects AT&T for New Network Services 2Health News:Howell Allen Clinic Selects AT&T for New Network Services 3Health News:Anthem Blue Cross and Blue Shield in Indiana Releases State Health Index 2Health News:Anthem Blue Cross and Blue Shield in Indiana Releases State Health Index 3Health News:Anthem Blue Cross and Blue Shield in Indiana Releases State Health Index 4
... (bDNA) delivers unmatched precision and reproducibility, so you ... viral load values they can trust.,you detect significant ... critical decision points - without the variability seen ... to choose VERSANT HIV bDNA, consider this: it's ...
... an FDA-approved HIV-1 RNA assay, is utilized for ... the regulatory approval for HIV-1 therapies, and is ... laboratories worldwide. , The AMPLICOR HIV-1 ... acid amplification test for the quantification of Human ...
... a single use rapid test, for the detection ... whole blood (venipuncture). Uni-Gold Recombigen HIV is intended ... an aid in diagnosis of infection with HIV-1. ... multi-test algorithms designed for the statistical validation of ...
The Becton™ Colles Fracture Plate has proven clinical outcomes and has excellent patient acceptance compared to external fixation. It provides a cost effective treatment option through a simple...
Medicine Products: